Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA

Cancer Immunology, Immunotherapy

Volumn 53, Issue 4, 2004, Pages 331-337

  Ullenhag, Gustav J ^a,b   Fagerberg, Jan ^b   Strigård, Karin ^b   Frödin, Jan Erik ^b   Mellstedt, Håkan ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CEA; HLA DR; T cell epitopes; Vaccination

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; RECOMBINANT CARCINOEMBRYONIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACULOVIRUS; CANCER IMMUNOTHERAPY; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; EPITOPE MAPPING; GENOTYPE; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 1642292805     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0441-4     Document Type: Article

References (36)

1. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP (1989) Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57:327
2. Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine B M, Rugarli C, Traversari C, Protti MP (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101:1038
3. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H (1995) Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 92:4773
4. Fields GB, Noble RL (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161
5. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169:575
6. Gulukota K, Sidney J, Sette A, DeLisi C (1997) Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol 267:1258
7. Hansson L, Rabbani H, Fagerberg J, Österborg A, Mellstedt H (2003) T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood
8. Harig S, Witzens M, Krackhardt AM, Trojan A, Barrett P, Broderick R, Zauls AJ, Gribben JG (2001) Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 98:2999
9. Hernandez J, Lee PP, Davis MM, Sherman LA (2000) The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 164:596
10. Horig H, Medina F, Conkright W, Kaufman H (2000) Strategies for cancer therapy using carcinoembryonic antigen vaccines. Expert reviews in molecular medicine
11. Huarte E, Sarobe P, Lasarte JJ, Brem G, Weiss EH, Prieto J, Borras-Cuesta F (2002) Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. Int J Cancer 97:58
12. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E (1999) Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 59:431
13. Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J (1999) Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17:332
14. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991
15. Maverakis E, Mendoza R, Southwood S, Raja-Gabaglia C, Abromson-Leeman S, Campagnoni AT, Sette A, Sercarz EE (2000) Immunogenicity of self antigens is unrelated to MHC-binding affinity: T-cell determinant structure of Golli-MBP in the BALB/c mouse. J Autoimmun 15:315
16. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK (1999) A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331
17. Mosolits S, Harmenberg U, Ruden U, Ohman L, Nilsson B, Wahren B, Fagerberg J, Mellstedt H (1999) Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol Immunother 47:315
18. Moudgil K D, Southwood S, Ametani A, Kim K, Sette A, Sercarz EE (1999) The self-directed T cell repertoire against mouse lysozyme reflects the influence of the hierarchy of its own determinants and can be engaged by a foreign lysozyme. J Immunol 163:4232
19. Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C (2000) Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 60:4850
20. Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I (1999) Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 80:92
21. Pardoll DM (1998) Cancer vaccines. Nat Med 4:525
22. Ras E, van der Burg SH, Zegveld ST, Brandt RM, Kuppen PJ, Offringa R, Warnarr SO, van de Velde CJ, Melief CJ (1997) Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol 53:81
23. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788
24. Samanci A, Yi Q, Fagerberg J, Strigard K, Smith G, Ruden U, Wahren B, Mellstedt H (1998) Pharmacological administration of granulocyte/macrophage- colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 47:131
25. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833
26. Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5:344
27. Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG (2001) Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 61:4761
28. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982
29. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H (2002) Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51:614
30. Ullenhag GJ, Frodin JE, Strigard K, Mellstedt H, Magnusson CG (2002) Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res 62:1364
31. van Ojik HH, Repp R, Groenewegen G, Valerius T, van de Winkel JG (1997) Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer. Cancer Immunol Immunother 45:207
32. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345
33. Zbar AP, Lemoine NR, Wadhwa M, Thomas H, Snary D, Kmiot WA (1998) Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target. Br J Cancer 77:683
34. Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF (2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 62:3630
35. Zsigo J, Saneii H (1994) A facile, efficient method for the simultanous synthesis of high-quality individual peptides: Application of ACT Model 350 for rapid multiple synthesis of peptides by solid phase method. In: Hodges R, Smith JA (eds) Peptides, chemistry, structure and biology. Proceedings of the 13th American Peptide Symposium. Escom, Leiden, p 91
36. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ (2002) Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 62:6187